Core Insights - Teleflex Incorporated has launched two initiatives to raise awareness about benign prostatic hyperplasia (BPH) during Men's Health Month, focusing on quality-of-life issues and potential rectal toxicity from prostate cancer radiation treatment [3][8]. Group 1: Awareness Initiatives - The initiatives include the "Prostate Monster" ad campaign and the Prostate Education Express, a mobile training center that will tour major U.S. cities throughout 2025 [4][5]. - The Prostate Education Express aims to educate both physicians and the community about BPH and the benefits of the UroLift™ System and Barrigel™ rectal spacer [4][7]. Group 2: UroLift™ System - The UroLift™ System is a minimally invasive treatment for BPH symptoms, indicated for men aged 45 and older, and has been used to treat over 500,000 men globally [10][6]. - A clinical study showed a low retreatment rate of about 2-3% per year, indicating the durability of the UroLift™ System [10]. Group 3: Barrigel™ Rectal Spacer - Barrigel™ rectal spacer is the first hyaluronic acid rectal spacer designed to protect the rectum during radiation therapy for prostate cancer, with over 50,000 men treated [12][8]. - A clinical study found that 98.5% of men treated with Barrigel™ achieved at least a 25% reduction in radiation to the rectum, with an average reduction of 85% [8].

Core Insights - Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System's advantages over Rezūm and tamsulosin in terms of early patient satisfaction, rapid symptom relief, and sexual function outcomes [2][3] Group 1: UroLift™ System Findings - The UroLift™ System demonstrated significantly higher patient satisfaction at two weeks and one month post-treatment compared to Rezūm, with shorter catheterization times and improved symptom relief [5] - At three months, patients treated with the UroLift™ System showed significantly better symptom improvement and sexual function outcomes compared to those on tamsulosin, with 70% of men on medication opting to switch to UroLift™ [5] - Real-world data from the American Urological Association Quality Registry (AQUA) confirmed that BPH drugs provide limited improvement, while the UroLift™ System offers rapid symptom score improvement at three months [5] Group 2: Safety of Stabilized Hyaluronic Acid (sHA) - The study confirmed the safety of stabilized hyaluronic acid as a rectal spacer, showing a low incidence of rectal wall infiltration and no severe complications, reinforcing its use during prostate cancer treatment [4][5] - The sHA rectal spacer allows for individualized spacing and is effective in protecting patients during radiation therapy, with a focus on its reversibility as a clinical advantage [4]